Discuss with your doctor or care team
Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.
Trial purpose
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
 |
NATIONAL TRIAL REFERENCE NUMBER | NCT04924075 |
 |
Conditions | Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers, Pancreatic Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma, Von Hippel-Lindau Disease |
 |
Age Range | 12+ |
 |
Sex | All |
|
Current trial phase | 1 |
|
Trial start and end dates | [08-12-2021] [06-04-2029] |
About the trial
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers, Pancreatic Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma, Von Hippel-Lindau Disease
All patients who enroll in the trial will receive medication while on the study.
100% will receive Belzutifan
Phase 2
In Phase 2 trials, researchers try to find out if a treatment works in about 100 to 500 participants – usually people who have the health condition the treatment is intended to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial locations (2)
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.